Pathstone Family Office, LLC Kintara Therapeutics, Inc. Transaction History

Pathstone Family Office, LLC

  • $15.6 Billion
  • Q3 2023

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Oct 23, 2023
BUY
$0.14 - $0.5 $1,400 - $5,000
10,000 New
10,000 $2,000
Q2 2022

Aug 15, 2022
BUY
$0.14 - $0.5 $1,400 - $5,000
10,000 New
10,000 $3,000

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Pathstone Family Office, LLC Portfolio

Follow Pathstone Family Office, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Family Office, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Family Office, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email